Dermatofitik onikomikozlarda aralıklı ve devamlı terbinafiıı tedavisi
Yükleniyor...
Dosyalar
Tarih
1997
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi Tıp Fakültesi Dergisi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Tırnak mantar enfeksiyonlarının tedavisi; oldukça zor, başarı oranlan nispeten düşük, tekrarlama ihtimali yüksek, uzun ve kullanılan ilaçların yan etkileri sebebiyle sık laboratuar kontrolleri gerektiren bir süreçtir. Triazoller (itrakonazol ve flukonazol) ve allilaminler (terbinafin) gibi yeni ilaçların kulanıma girmesi; tam iyileşme oranlarını yükseltmiş, etki spektrumunu genişletmiş, tedavi sürelerini kısaltmış ve yan etkileri kısmen azaltmıştır. Elde edilen ilk sonuçlar terbinafin'in, itrakonazol kadar geniş spektrumlu olmamakla beraber, onikomikoz tedavisinde oldukça etkili olduğunu göstermektedir. Terbinafin, tedavi kesildikten sonra da uzunca bir süre tırnaklarda etkili bir konsantrasyonu korumaktadır. Onikomikoz tedavisinde aralıklı ve devamlı terbinafin kullanımının etkinliğini karşılaştırmak amacıyb yaptığımız bu çalışmada, devamlı tedavi grubunda klinik ve mikroskopik iyileşme oranlarının aralıklı tedavi grubuna göre daha yüksek olduğunu fakat aradaki farkın istatistik açıdan anlamlı olmadığını gördük. Dermatofitik onikomikozların tedavisinde devamlı terbinafin uygulamasının tercih edilmesi gerektiği sonucuna vardık.
The treatment of onychomycosis is a difficult and long-standing course because of the relatively low success and high recurrence rates and the necessity of laboratory monitoring for the traditional oral antifungal agents. The introduction of newer systemic antifungal drugs such as triazoles (itraconazole and fluconazole) and allylamines (terbinafine) offer an increased cure rate, a broader spectrum of activity, shortening of the treatment period, and increased safety, compared with the traditional systemic antifungal drugs (griseofulvin and ketoconazole). Preliminary results suggest that terbinafine is promising in the treatment of onychomycosis, although its spectrum of activity is not as broad as that of itraconazole. Terbinafine persists in the nails at effective concentrations for a long time even after discontinuation of treatment. An open randomized study was planned to compare the efficacy of intermittent and continuous terbinafine regimens. The clinical and microscopic cure rates were higher in the continuous group than in the intermittent group, but the differences between two groups were not statistically significant. It is suggested that continuous terbinafine regimen should be preferred in the treatment of dermatophytic onychomycosis.
The treatment of onychomycosis is a difficult and long-standing course because of the relatively low success and high recurrence rates and the necessity of laboratory monitoring for the traditional oral antifungal agents. The introduction of newer systemic antifungal drugs such as triazoles (itraconazole and fluconazole) and allylamines (terbinafine) offer an increased cure rate, a broader spectrum of activity, shortening of the treatment period, and increased safety, compared with the traditional systemic antifungal drugs (griseofulvin and ketoconazole). Preliminary results suggest that terbinafine is promising in the treatment of onychomycosis, although its spectrum of activity is not as broad as that of itraconazole. Terbinafine persists in the nails at effective concentrations for a long time even after discontinuation of treatment. An open randomized study was planned to compare the efficacy of intermittent and continuous terbinafine regimens. The clinical and microscopic cure rates were higher in the continuous group than in the intermittent group, but the differences between two groups were not statistically significant. It is suggested that continuous terbinafine regimen should be preferred in the treatment of dermatophytic onychomycosis.
Açıklama
[Journal of Turgut Özal Medical Center 1997;4(2):135-138]
Anahtar Kelimeler
Onychomycosis, Terbinafine, İntermittent therapy, Onikomikoz, Terbinafin, Aralıklı tedavi
Kaynak
Turgut Özal Tıp Merkezi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
4
Sayı
2
Künye
Şenol, M.,Özerol, İ. H.,Şaşmaz, S.,Özcan, A.,Soytürk, D.,(1997). Dermatofitik onikomikozlarda aralıklı ve devamlı terbinafiıı tedavisi.Turgut Özal Tıp Merkezi Dergisi, 4 (2).135-138 ss.
